Ligand Pharmaceuticals Incorporated LGND

Updated: 12 Sep 2026

NASDAQ | Royalty Company | Biopharmaceutical royalties and licensing

No signal published yet

We already track Ligand Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Ligand Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Royalty Company
Sector
Biopharmaceutical royalties and licensing
We're already tracking Ligand Pharmaceuticals Incorporated — here are the latest events we've registered

Recent News

  • On July 14, 2026, Ligand completed the acquisition of XOMA Royalty Corporation for approximately $739 million in cash, adding over 120 commercial and clinical-stage royalty assets to its portfolio. On August 6, 2026, the company reported second-quarter 2026 financial results, with royalty revenue increasing 32% year-over-year to $48.0 million, leading management to raise the lower end of its full-year adjusted EPS guidance.

What Firelda Watch includes for Ligand Pharmaceuticals Incorporated

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Ligand Pharmaceuticals Incorporated will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Viper Energy, Inc.
VNOM
HOLD

Royalty Companies

More companies in this sector

Want to follow Ligand Pharmaceuticals Incorporated? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Ligand Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Ligand Pharmaceuticals Incorporated LGND
Ligand Pharmaceuticals — follow and we'll monitor it
Follow Ligand Pharmaceuticals free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.